-+ 0.00%
-+ 0.00%
-+ 0.00%

AstronauTx exercises option with Saniona, issues shares worth USD 5 million for ATX0926 rights

PUBT·08/10/2026 06:03:56
Listen to the news
AstronauTx exercises option with Saniona, issues shares worth USD 5 million for ATX0926 rights
  • AstronauTx exercised its option under a 2023 research collaboration with Saniona to secure exclusive worldwide rights to the ATX0926 neurological disease program.
  • ATX0926 is expected to enter IND-enabling studies shortly, shifting control of development, manufacturing, and commercialization to AstronauTx.
  • Saniona will receive Series A shares in AstronauTx valued at USD 5 million, booked as income and an equity investment.
  • The deal includes eligibility for up to USD 172 million in milestones, split between development and regulatory milestones and commercial milestones.
  • Saniona also qualifies for tiered royalties on net sales if products from the program reach the market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.